Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
Alphamethyldopa has been found to prolong the biological half-lives of Antipyrine and Tolbutamide and to decrease D-glucaric acid excretion in man. These observations suggest that the liver microsomal enzyme system metabolizing drug in man is inhibited by alphamethyldopa. No side effects were found during treatment with alphamethyldopa at the dose levels used in this study.
D000328:Adult; D000983:Antipyrine / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D005937:Glucaric Acid / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000009:adverse effects / Q000494:pharmacology*; D008875:Middle Aged; D013400:Sugar Acids / Q000378:metabolism*; D014044:Tolbutamide / Q000378:metabolism*; D005723:gamma-Glutamyltransferase / Q000097:blood
D013400:Sugar Acids; D008750:Methyldopa; D014044:Tolbutamide; D005723:gamma-Glutamyltransferase; D005937:Glucaric Acid; D000983:Antipyrine